Renal Cell Carcinoma

In the first article of a 2-part series, Rana McKay, MD, goes through the updated data from the CheckMate 9ER trial that supports the continued use of the combination of nivolumab and cabozantinib for patients with metastatic clear cell renal cell carcinoma.

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.

IVS-3001, a chimeric antigen receptor therapy developed to target and kill HLA-G-bearing cells, is currently in late-stage preclinical development for the treatment of solid tumors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tian Zhang, MD, and participants discussed factors that drive their choice of first-line therapy for patients with advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro Barata, MD, MSc, discussed the CheckMate 9ER, KEYNOTE-426, and CLEAR trials of frontline combination therapies for patients with renal cell carcinoma.

In the second article of a 2-part series, Hans Hammers, MD, PhD, leads a discussion on the adverse events seen with the use of tyrosine kinase inhibitors in the treatment of patients with renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Nizar M. Tannir, MD, discussed with participants their experiences with the combination of lenvatinib and pembrolizumab, including the dosing schedule of pembrolizumab and finding a tolerable dose of lenvatinib.

Eric A. Singer, MD, discusses recent research evaluating adjuvant therapies for patients with high-risk renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Campbell, MD, MS, discussed guidelines and available therapies for a patient who requires second-line treatment and beyond for metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, and participants discussed using immunotherapy plus tyrosine kinase inhibitor to treat advanced renal cell carcinoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology, Yann-Alexandre Vano, MD, discussed the implications of the findings from the phase 2 BIONIKK trial of second-line treatment for patients with metastatic RCC.

At a live, virtual Case-Based Roundtable meeting, Bradley McGregor, MD, discussed with fellow physicians how best to integrate new approaches to treatment for patients with relapsed or refractory clear cell renal cell carcinoma.

In the fifth article of this series, Hans Hammers, MD, PhD, outlines established treatment paradigms and discusses clinical trial data and ongoing research that are informing the future treatment landscape of advanced renal cell carcinoma.

During a Targeted Oncology™ Community Case Forum™ event, Hans Hammers, MD, discussed trials that shed light on the role of adjuvant therapies for patients with stage II and III renal cell carcinoma.

Samer A. Srour, MD, discusses the results of the phase 1 TRAVERSE trial of ALLO-316 in patients with advanced renal cell carcinoma.

Eric Singer, MD, discusses the relevant data that led to the approval of sunitinib in the adjuvant treatment setting for renal cell carcinoma.

In part 1 of a 2-part series, Hans Hammers, MD, PhD, discusses the current landscape for treating patients with advanced renal cell carcinoma who have had 1 or 2 prior therapies and how tivozanib fits into current treatment practices.

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth M. Wulff-Burchfield, MD, and participants discussed the choice of frontline options for a patient with favorable-risk clear cell renal cell carcinoma, and how liver or lung metastases affect the decision.

VEGFR inhibitors, mTOR inhibitors, and immune checkpoint inhibitors have been studied as adjuvant therapy for patients with RCC. However, conflicting data from phase 3 trials have left investigators unclear on what their role is.

Combining sintilimab and axitinib led to tumor shrinkage and a tolerable safety profile in patients with advanced FH-deficient renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta Kumar Pal, MD, and participants discussed next-line therapy for a patient with advanced clear cell renal cell carcinoma who progressed on axitinib/pembrolizumab and single-agent cabozantinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, MS, discussed with participants how risk groups affect their choice of first-line treatment in renal cell carcinoma. This is the first of 2 articles based on this event.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.

The immunotherapy and tyrosine kinase inhibitor combination cabozantinib plus nivolumab and piplimumab induces response in nearly half of patients treated.

Positive results have been reported from phase 1/2 KEYMAKER-U03B study, and belzutifan plus lenvatinib is being further investigated in the phase 3 LITESPARK-011 study (NCT04586231).

A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.

Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.